Skip to main content
U.S. flag

An official website of the United States government

L-3-n-butylphthalide improves cognitive impairment and reduces amyloid-beta in a transgenic model of Alzheimer's disease

BIBLIOGRAPHIC THERAPEUTIC AGENT ANIMAL MODEL EXPERIMENTAL DESIGN OUTCOMES

Bibliographic

Year of Publication:
2010
Contact PI Name:
Cynthia A. Lemere
Contact PI Affiliation:
Center for Neurologic Diseases, Boston, Massachusetts, USA
Co-Authors:
Ying Peng, Jing Sun, Stephanie Hon, Alyssa N. Nylander, Weiming Xia, Yipu Feng, Xiaoliang Wang
Primary Reference (PubMED ID):
20554868
Funding Source:
Alzheimer's Association
Study Goal and Principal Findings:

The aim of this study was to examine the effect of the natural product L-NBP( L-3-n-Butylphthalide) on cognitive impairment in a triple transgenic mouse model of AD (3xTg-AD) and to examine  the mechanisms underlying the efficacy of the compound, namely its activity on APP processing, Abeta generation, Abeta clearance and glial activiation.The data demonstrated data that L-NBP was able to reduce cerebral Abeta levels, glial activation, oxidative stress, and cognitive impairment in the  In addition, the data showed that L-NBP regulated APP processing toward the non-amyloidogenic pathway and promoted sAPPalpha release, thereby precluding Abeta generation. L-NBP appears to be promising as a multi-target drug for the prevention and/or treatment of Alzheimer’s disease. 

Therapeutic Agent

Therapeutic Information:
Therapy Type:
Natural Product
Therapeutic Agent:
L-3-n-Butylphthalide
PubMed
PubChem
DrugBank
ClinicalTrials
Patents
Therapeutic Target:
Multi Target

Animal Model

Model Information:
Species:
Mouse
Model Type:
APPxPS1xTau
Model Name:
3xTg
ALZFORUM
Strain/Genetic Background:
C57BL/6

Experimental Design

Is the following information reported in the study?:
Power/Sample Size Calculation
Randomized into Groups
Blinded for Treatment
Blinded for Outcome Measures
Pharmacokinetic Measures
Pharmacodynamic Measures
Toxicology Measures
ADME Measures
Biomarkers
Dose
Formulation
Route of Delivery
Duration of Treatment
Frequency of Administration
Age of Animal at the Beginning of Treatment
Age of Animal at the End of Treatment
Sex as a Biological Variable
Study Balanced for Sex as a Biological Variable
Number of Premature Deaths
Number of Excluded Animals
Statistical Plan
Genetic Background
Inclusion/Exclusion Criteria Included
Conflict of Interest

Outcomes

Outcome Measured
Outcome Parameters
Behavioral
Morris Water Maze
Motor Function
Swimming Speed
Histopathology
beta Amyloid Load
Activated Microglia
Activated Astrocytes
Biochemical
Brain-beta Amyloid Peptide-Total
Amyloid Precursor Protein (APP) Metabolites
A Disintegrin and Metalloproteinase Domain 10 (ADAM10)
A Disintegrin and Metalloproteinase Domain 17 (ADAM17)
Protein Kinase C alpha (PKC alpha)
Immunochemistry
phospho-Tau
Share:
Print: